CenterHigh
Financial Times - CompaniesNews report · Jul 9, 7:35 AM
Astra Zeneca shares slide 9% after heart treatment disappoints in trial
UK pharmaceutical company says Wainua drug did not meet goal of reducing cardiovascular deaths
← Today's headlines
3 sources checked · 2 source groups included · 30m ago
Still Watching
Astra Zeneca shares slide 9% after heart treatment disappoints in trial
UK pharmaceutical company says Wainua drug did not meet goal of reducing cardiovascular deaths
1 Left2 Center0 Right
STILL WATCHING
As of July 9, 2026 at 9:13 AM, this is how Optics News reads the wording differences in this story.
What happened UK pharmaceutical company says Wainua drug did not meet goal of reducing cardiovascular deaths.
The headline split The left frames it as "Astra Zeneca stock dives 9% after heart drug trial misses target". The center frames it as "STAT+: Astra Zeneca, Ionis report major trial failure with heart disease drug".
Match confidence Medium confidence. 3 sources across 2 bias buckets. Useful framing signal — check the source list before sharing.
Same-event confidenceMedium
3 sources across 2 bias buckets agree on the event.
Framing confidenceModerate
56/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
Left / center-leftAstra Zeneca stock dives 9% after heart drug trial misses target
CNBC · Center-left · News report
CenterAstra Zeneca shares slide 9% after heart treatment disappoints in trial
Financial Times - Companies · Center · News report
Right / center-rightNo matching source in this bucket yet.
Optics keeps watching for pickup.
SEE THE HEADLINES
Open source
CenterHigh
STAT NewsNews report · Jul 9, 9:13 AM
STAT+: Astra Zeneca, Ionis report major trial failure with heart disease drug
stationismajorfailure
Astra Zeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.
Center-leftMostly Factual
CNBCNews report · Jul 9, 8:53 AM
Astra Zeneca stock dives 9% after heart drug trial misses target
stockdivesaftermissestarget
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
Details56/99 Wording Gap · Medium confidence · 3 sources
56/99 Wording GapMedium confidence3 sources · 2 bias bucketsLive match · 3 sources · 2 buckets · comparable news formatFormats: News report
SOURCE MAP CHANGES
Jul 9, 7:35 AM: Financial Times - Companies joined the source map.
Jul 9, 8:53 AM: CNBC joined the source map.
Jul 9, 9:13 AM: STAT News joined the source map.
Now: Wording Gap is 56/99 and story health is live match · 3 sources · 2 buckets · comparable news format.